Kiniksa Pharmaceuticals Ltd. (KNSA)
| Market Cap | 558.36M |
| Revenue (ttm) | 70.73M |
| Net Income (ttm) | -133.65M |
| Shares Out | 69.28M |
| EPS (ttm) | -2.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,542 |
| Open | 8.49 |
| Previous Close | 8.70 |
| Day's Range | 7.93 - 8.88 |
| 52-Week Range | 7.56 - 16.68 |
| Beta | -0.03 |
| Analysts | Buy |
| Price Target | 23.72 (+194.3%) |
| Earnings Date | May 3, 2022 |
About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arter...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for KNSA stock is "Buy." The 12-month stock price forecast is 23.72, which is an increase of 194.29% from the latest price.
News
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.77% and 0.83%, respectively, for the quarter ended March 2022.
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST ® (rilonacept) net revenue of $22.2 million in Q1 2022 –
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m...
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -20.45% and 14.86%, respectively, for the quarter ended December 2021.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
– ARCALYST ® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 – – ARCALYST collaboration achieved profitability in Q4 2021 – – ARCALYST full-year 2022 net revenue expected ...
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
– Collaboration includes rights to develop and commercialize ARCALYST ® and mavrilimumab in the Asia Pacific Region (excluding Japan) –
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022, at 8...
Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan...
Wall Street Analysts See a 151% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 150.6% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is que...
Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal
Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.
Why Kiniksa Pharmaceuticals Stock Is Falling Today
Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is trading lower Tuesday morning after the company announced the Phase 3 trial of mavrilimumab in COVID-19-related ARDS did not meet the primary efficacy endpo...
Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological p...
Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Kiniksa Pharmaceuticals, Ltd. (KNSA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference
HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual Healt...
Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 138% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 137.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend ...
Wall Street Analysts Think Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Surge 100%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 100.2% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is que...
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.16% and 21.93%, respectively, for the quarter ended September 2021.
Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution
- Q3 2021 ARCALYST ® (rilonacept) net revenue of $12.1 million - - ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval - - Data from Phase 3 trial of mavrilimumab i...
Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021
HAMILTON, Bermuda, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at 8:3...
Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference...
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 11.59% and 200.94%, respectively, for the quarter ended June 2021.
Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
- Q2 2021 ARCALYST ® (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians -
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, Augus...
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 ...
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological p...